145 related articles for article (PubMed ID: 17563734)
1. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy.
Saito AM; Zahrieh D; Cutler C; Ho VT; Antin JH; Soiffer RJ; Alyea EP; Lee SJ
Bone Marrow Transplant; 2007 Aug; 40(3):209-17. PubMed ID: 17563734
[TBL] [Abstract][Full Text] [Related]
2. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M
Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942
[TBL] [Abstract][Full Text] [Related]
3. Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors.
Hows JM; Passweg JR; Tichelli A; Locasciulli A; Szydlo R; Bacigalupo A; Jacobson N; Ljungman P; Cornish J; Nunn A; Bradley B; Socié G; ;
Bone Marrow Transplant; 2006 Dec; 38(12):799-805. PubMed ID: 17075568
[TBL] [Abstract][Full Text] [Related]
4. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
[TBL] [Abstract][Full Text] [Related]
5. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
[TBL] [Abstract][Full Text] [Related]
7. Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies.
Kim I; Yoon SS; Lee KH; Keam B; Kim TM; Kim JS; Kim HG; Oh MD; Han KS; Park MH; Park S; Kim BK
Clin Transplant; 2006; 20(4):496-503. PubMed ID: 16842528
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
10. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
[TBL] [Abstract][Full Text] [Related]
11. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
12. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
[TBL] [Abstract][Full Text] [Related]
13. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
14. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse.
Yakoub-Agha I; Saule P; Magro L; Cracco P; Duhamel A; Coiteux V; Bruno B; Dufossé F; Jouet JP; Dessaint JP; Labalette M
Biol Blood Marrow Transplant; 2009 Apr; 15(4):496-504. PubMed ID: 19285638
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
[TBL] [Abstract][Full Text] [Related]
16. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
18. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of unrelated donor umbilical cord blood transplantation for 30 adults with hematological malignancies.
Kobayashi K; Maeda Y; Hara Y; Nishie-Kataoka M; Nishimori H; Sugiyama H; Namba N; Kubonishi S; Niiya M; Shinagawa K; Ikeda K; Tanimoto M
Anticancer Res; 2009 May; 29(5):1763-70. PubMed ID: 19443401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
